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Introduction 
 
Primary immunodeficiency diseases (PID) are 
characterized by defects in the immune system, 
mainly due to single gene defect (1). This hetero-
geneous, inherited group of diseases led to absent 
or reduced function in one or more components 
of the immune system, leading to variable im-
mune-related complications (2). 
Recurrent mucosal infections, persistent fungal 
infection, deep organ abscesses, enteropathy, 
granulomatous lesions, opportunistic infections, 
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autoimmunity, lymphoproliferative disorders, and 
malignancies are the most important manifesta-
tions of PID patients (3, 4). Early detection, pre-
venting complications, and adequate treatments 
are the keys to reducing morbidity and mortality 
of patients (5-7). Although the true prevalence of 
PID is unknown, it is not considered as a rare 
condition (8-11). Physician awareness could lead 
to better identification of diseases. Although 
prevalence of each type of PID differs from oth-
ers, ethnicity and consanguinity could change the 
incidence pattern of disease, especially in those 
with autosomal recessive inheritance (12, 13). 
Patients with PID usually experience several hos-
pital admissions, especially in emergency, immu-
nology, and infectious diseases wards (14, 15). 
Antibiotic and antifungal agents are the mainstay 
treatment to control, prevent and manage chron-
ic and recurrent infections. Immunoglobulin re-
placement therapy both intravenously and subcu-
taneously is another effective therapy in antibody 
deficiencies, also recommended for treatment of 
many patients with other forms of PID associat-
ing hypogammaglobulinemia (5). Other therapeu-
tic approaches include cytokine therapy, enzyme 
replacement, vaccinations and hematopoietic 
stem cell transplantation (HSCT) (5).  
Nowadays, economic analyses importance has 
been at the center of attention also in health sys-
tem, predominantly with respect to health policy 
making for specific diseases and pharmaceutical 
recourses (16). In this cost-conscious environ-
ment, it is important to evaluate exact costs of 
diseases to choose less therapeutic modalities 
with high effectiveness to achieve better out-
comes (17). This valuable knowledge will illumi-
nate treatment guideline and health budgeting. 
One of the most important sections of estimating 
financial burden of disease is admission cost, 
which is crucial for proper decision-making 
process. Evaluation of admission expenditures 
can assist health care providers into two goals of 
budget assignment for medication and cares as 
well as investigating efficiency of different health 
interventions by means of either cost-benefit or 
cost-effectiveness analysis (18). Although burden 
of some special PID disease was measured (19-
21), there is no specific data regarding the cost 
and economic burden of whole PID group.  
This study was designed to estimate the admis-
sion cost of PID in the main referral hospital.  
 
Materials and Methods 
 
Study environment 
During the period of study from Jan 2011 to Jan 
2012, the patients with diagnosis of PID hospita-
lized in the Children’s Medical Center Hospital, 
Tehran, Iran were enrolled in the study. This hos-
pital is the Pediatrics Center of Excellence in Iran 
affiliated to Tehran University of Medical Sciences, 
also known as the main referral center for PID pa-
tients. The research center for immunodeficiency 
located in this hospital is the documenting center of 
European society for Immunodeficiency and PID 
patients are diagnosed and treated in this center 
based on the updated standardized guidelines (22). 
Therefore, the registered costs for the patients ad-
mitted to this tertiary center can be a representative 
for direct economic costs due to hospitalization in-
patient with definite PID diagnosis.  
The process of this study was approved by the 
Ethics Committee of the Tehran University of 
Medical Sciences, Iran and the extracted data 
were anonymized for further analysis. 
 
Patient recruitment  
The patients were included in the survey, based 
on the International Classification of Diseases-10 
(ICD-10) code, which extracted from Chapter III 
(Diseases of the blood and blood-forming organs 
and certain disorders involving the immune me-
chanism; D50-D89) (23). The following patients 
categories were included: D83.9: Common varia-
ble immunodeficiency; D81.9: Combined immu-
nodeficiency; D80.4: Selective deficiency of IgM; 
D80.2: Selective deficiency of IgA; D71: Chronic 
granulomatous disease; D82.4: Hyper IgE syn-
drome; D70: Agranulocytosis (for just patients 
with severe congenital neutropenia); D80.0: X-
linked agammaglobulinemia; D82.0: Wiskott-
Aldrich syndrome; D84.9: Immunodeficiency, 
unspecified (for other defined PID, not specified 
in the ICD-10) (24, 25).  
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Medical records 
The electronic medical records of all patients 
with PID were extracted from hospital informa-
tion system (HIS) during the period of study. 
Collective information on demographic data 
(gender, age, number of admissions, length of 
admission, season of admission and ICD code), 
and variable medications and other health care’s 
costs of admission were recorded. HIS database 
record the kind and frequency of hoteling facili-
ties, hospital bed occupancy, medication (e.g. 
drugs, fluids administered), consumables (e.g. 
syringes, tubes, and catheters), para-clinical ana-
lyses (e.g. laboratory tests, imaging, pathological 
investigation), and interventional procedures (e.g. 
surgery, bronchoscopy) were all evaluated in total 
cost of admission for each individual patient. We 
categorized all drugs cost into 12 groups, accord-
ing to anatomical-therapeutic-chemical (ATC) 
code of World Health Organization (26); then we 
calculated the cost of each group individually and 
in different strata of PID. After data extraction, 
total admission related costs were calculated by 
addition of all counted costs and converted to US 
dollar, based on currency exchange in the same 
period in 2011 as previously described (27). 
 
Statistical analysis 
Statistical analysis was performed using SPSS sta-
tistical software package (SPSS Statistics 17.0.0, 
(Chicago, IL, USA). One-sample Kolmogorov-
Smirnov test estimated whether data were nor-
mally distributed. Parametric and nonparametric 
analyses were performed based on the finding of 
this evaluation. A P-value of 0.05 or less was con-
sidered statistically significant.  
 
Results 
 
Patients’ characteristics 
One hundred and ten patients with PID were 
admitted the Children’s Medical Center in 2011, 
including 65 males and 45 females. Patients with 
combined immunodeficiency (27 cases with 
ICD10: D81.9) were the most frequent type of 
PID admitted in the hospital (Table 1). The aver-
age age of patient at the time of admission was 
5.9±3.7 yr, ranging from 19 d to 18 yr old, while 
average length of admission was 16.33±14.7 d 
(range of 1 d to 2 months). 
 
Admission costs 
The mean cost of admission was 
7090.4±2663.9$, ranging from 447$ to 256.000$.  
Table 1: Data analysis on cost of admission in different types of primary immunodeficiency diseases 
 
ICD 10  Disease Number of 
patients 
M/F Cost 
mean 
SD Drug cost 
percentage 
(%) 
SD 
D83.9 Common variable immunodeficiency,  
unspecified 
18 11/7 2367.0 368.7 11.19 2.2 
D81.9 Combined immunodeficiency, unspecified 27 13/14 2096.2.6 499.2 28.1 7.2 
D80.4 Selective deficiency of IgM 5 5/0 7675.2 1440.6 9.3 7.1 
D80.2 Selective deficiency of IgA 7 5/2 1148.8 1011.8 7.7 4.9 
D71 Chronic granulomatous disease 15 12/3 5716.0 1462.2 9.9 6.5 
D82.4 Hyper Ig E syndrome 12 2/10 2591.0 663.8 22.4 2.8 
D70 Agranulocytosis 8 3/5 2582.2 415.1 11.1 7.8 
D80.0 X linked agammaglobulinemia 1 1/0 285 - 4.6 - 
D82.0 Wiskott Aldrich syndrome 2 2/0 2327 - 8.7 - 
D84.9 Immunodeficiency, unspecified 15 11/4 3925.3 940.2 16.5 9.5 
 
The mean cost of admission per day was esti-
mated about 284.7$. Comparison of the cost of 
admission in different types of PID failed to 
show any significant difference between the 
amounts of payments (F=1.30, P=0.2).  
Drug costs 
The mean cost of drugs and medications was 
1579.8±498.6$; 17.2±3.9 percent of total medical 
costs. The mean cost of drug per day of admis-
sion was estimated about 90$. 
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The greatest mean costs of drug groups belonged 
to anti-infective for systemic use (770$) which 
followed by alimentary tract and metabolism 
(464$) and blood and blood forming organs 
agents (168$). Investigation of anti-infective 
group internally showed that immune sera and 
immunoglobulin with 219$ and antiviral agents 
for systemic use with 159$ consist the most im-
portant medication for PID patients during hos-
pital admission (Table 2). 
  
Table 2: Data analysis on cost of medications and drug in different types of primary immunodeficiency diseases 
 
Drug groups Total 
Cost 
D83.9 D81.9 D80.4 D80.2 D71 D82.4 D70 D84.9 
Anti-infective for sys-
temic use 
770.5±215.
2 
745.1±86.
7 
2005.2±396.
1 
502.2±63.
3 
78.6±7.1 497.3±108.
7 
176.9±53.
1 
160.8±27.
8 
181.7±42.
1 
Beta-lactam antibacterials, 
penicillins 
59.9±17.9 22.1±6.4 140.2±28.1 1.3±0.1 0 47.3±18.1 53.1±17.6 0.3±0.08 58.0±13.9 
Other beta-lactam antibac-
terials 
91. 3±24.9 34.7±7.5 224.9±43.5 53.7±7.2 30.9±4.7 109.1±23.8 15.7±2.4 87.1±14.8 18.8±3.1 
Sulfonamides and 
trimethoprim 
40.9±18.5 10.9±2.9 120.0±35.5 86.0±19.2 7.4±0.6 17.1±2.7 20.0±5.9 0.09±0.02 5.3±1.4 
Macrolides, lincosamides 
and streptogramins 
24.4±9.9 7.2±1.4 55.0±18.2 73.7±16.2 3.9±0.08 27.3±4.0 0.6±0.1 17.9±4.6 6.0±1.0 
Aminoglycoside antibacteri-
als 
3.4±1.8 0.6±0.2 10.9±3.7 0 0.1±0.04 2.4±0.06 1.0±0.5 0 0.6±0.2 
Other antibacterials 102.7±49.0 29.4±8.7 311.2±96.7 11.2±2.5 22.5±3.2 43.8±8.9 39.7±13.1 54.5±8.8 32.8±8.9 
Quinolone antibacterials 37.2±21.5 11.8±3.8 52.0±23.5 0 0.08±0.0
2 
164.8±48.1 0 0 0 
Antivirals for systemic use 159.6±73.3 0.9±0.3 76.5±21.4 0.4±0.1 6.2±1.0 78.8±18.8 3.5±0.7 0.7±0.2 4.5±1.2 
Antimycotics for systemic 
use 
30.7±12.9 0.5±0.02 0.7±0.2 0 0.1±0.04 0.1±0.03 0 0 0 
Antimycobacterials 0.2±0.01 35.7±13.4 568.9±140.5 0 7.0±1.8 10.2±3.9 42.4±14.9 0 46.6±21.0 
Immune sera and immu-
noglobulin 
219.6±67.1 589.6±73.
1 
444.4±110.5 275.5±61.
6 
0 0 0 0 8.66±3.7 
Drug for sensory or-
gans 
0.38±0.17 0 0.7±0.2 0.1±0.02 0.05±0.0
1 
0.06±0.01 1.3±0.3 0 0.44±0.1 
Dermatological agents 3.5±1.2 0.1±0.06 6.1±1.4 1.8±0.4 0.8±0.1 1.2±0.3 6.0±1.9 0.2±0.05 6.1±2.0 
Drug for respiratory 
system 
22.0±10.8 10.7±2.8 57.1±21.2 14.5±1.3 13.1±1.7 9.3±3.1 10.2±3.3 20.9±5.9 5.3±1.2 
Drug for blood and 
blood forming organs 
168.1±54.4 179.2±52.
6 
511.5±93.7 5.4±1.0 75.8±20.
0 
10.8±3.8 34.3±9.7 2.3±0.2 17.9±4.1 
Drug for alimentary 
tract and metabolism 
464.0±172.
6 
186.2±40.
4 
1407.4±330.
1 
132.2±26.
8 
53.2±7.4 178.6±31.7 88.1±19.3 230.4±60.
2 
166.6±34.
2 
Drug for nervous sys-
tem 
15.8±4.4 2.0±0.6 26.7±5.1 8.0±1.7 0.6±0.1 18.4±4.5 30.4±8.9 12.1±3.2 12.2±3.2 
Drug for musculoskele-
tal system 
0.6±0.05 0 0.17±0.01 0 0 0.18±0.07 0 0 0.06±0.05 
Drug for cardiovascular 
system 
18.1±8.8 0.8±0.3 25.9±8.7 0 0.2±0.05 2.6±0.9 106.4±23.
3 
5.3±1.4 1.1±0.2 
Drug for antineoplastic 
and immunomodulat-
ing agents 
16.3±7.0 0 24.5±7.7 0 0 0 9.8±2.2 100.2±19.
5 
11.8±5.1 
Systemic hormonal 
preparations, excl. sex 
hormones and insulin 
94.5±77.6 17.9±5.6 332.7±155.3 182.3±40.
7 
5.2±1.3 2.1±0.7 0.7±0.2 7.1±2.0 2.6±0.7 
Various 10.8±3.0 6.5±2.2 24.7±5.1 0 0 12.0±2.2 0 17.6±3.5 4.6±0.9 
D83.9: Common variable immunodeficiency, unspecified, D81.9: Combined immunodeficiency, unspecified, D80.4: 
Selective deficiency of IgM, D80.2: Selective deficiency of IgA, D71: Chronic granulomatous disease, D82.4: Hyper 
IgE syndrome, D70: Agranulocytosis, D84.9: Immunodeficiency, unspecified 
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Drug costs in PID groups 
Drug cost during admission consisted 4.6% to 
28.1% of the total admission costs, based on type 
of PID; however, this variability was not statisti-
cally significant (F=0.52, P=0.81, Table 1).  
Table 2 abstracted the cost of different groups of 
drugs, based on the PID disorders. Each drug 
group cost was evaluated internally for different 
PID to find which disease need more cost for 
special drugs. Cardiovascular system agents were 
used more in admission of chronic granulomat-
ous disease patients in contrast with admission of 
common variable immunodeficiency (scheffe 
analysis: P=0.018) and hyper IgE syndrome 
(scheffe analysis: P=0.024). Combined immuno-
deficiency had higher rate of utilizing blood-
forming drugs in comparison of chronic granu-
lomatous disease (P=0.027). In the other hand, 
antineoplastic therapeutic agents were consumed 
in higher rate in common variable immunodefi-
ciency cases rather than agranulocytosis and 
chronic granulomatous disease patients (P=0.011 
and P=0.014, respectively). 
 
Effect of different variables on drug costs 
Comparison of admission costs of PID in differ-
ent seasons showed higher mean cost of admis-
sion (12940±4732.6$) and mean cost of drugs 
(2620.7 ±873.8$) in winter, but such differences 
were not significant (F=0.53, P=0.66; Fig. 1). 
There was no association between age of PID 
patients and the admission cost (r=-0.16, 
P=0.09).  
 
 
 
Fig. 1: Cost of admission (red line) and drugs (blue line) of primary immunodeficiency patients during different sea-
sons; spring (n=23), summer (n=24), fall (n=33), and winter (n=29) 
 
Discussion 
 
There are limited data on admission and drug 
costs of PID treatment, though many studies ac-
companied about immunoglobulin costs (28-36). 
Although calculation of other drugs costs and 
modalities on PID is necessary, no study has 
been accomplished so far. Costs of medications 
only consist about one-fourth to one-third of 
total cost of PID patients during the hospitaliza-
tion period.  
Consideration of main cost drivers for admission 
of PID patients leads policy makers to provide a 
program to enhance patient outcomes and im-
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prove quality of life besides lowering costs. Mak-
ing some structure and strategy, in the end, could 
be translated into critical cost saving to an organ-
ization.  
Our findings showed the higher admission rate in 
the combined immunodeficient patients, while 
the predominantly antibody deficiency are the 
most frequent diagnosed group of patients based 
on the recently published report of national regi-
stry (22). Although this phenomenon is reasona-
ble due to the nature of the immune defects in 
these patients comparing to other groups of pa-
tients, this group of disorder can be screened for 
newborns (facilitating finding of donor and pre-
vention of side effect of immunization with lived 
vaccine) and can be cured by HSCT (37). 
Moreover current reports on the significant direct 
burden of PID can also indicate the necessity of 
fund allocation for molecular diagnosis for find-
ing the genetic defects in the patients and subse-
quently on their relative for carrier detection and 
for helping by genetic consultation, prenatal di-
agnosis and/or preimplantation genetic diagnosis 
(38). This approach is not only according to the 
model for reduction of incidence and prevalence 
of autosomal receives disorders in the country 
with higher rate of consanguinity. However it can 
reduce the rate of X-linked disorders as in our 
study the majority of patients were male and this 
could be due to the presence of PID with X-
chromosome inheritance (e.g. X-linked agam-
maglobulinemia, X-linked hyper IgM and X-
linked severe combined immunodeficiency) in 
which carrier detection is essential in all female 
siblings and maternal aunts (1, 39).  
Conformity of drug costs in the patients with the 
specific complication of each PID group and ab-
sence of correlation between age and admission 
cost suggests that the direct economic burden of 
PID disease forced in the long term in the af-
fected children.  
Two of every five PID patients are missing phy-
sician or hospital care, or failing to fill their pre-
scription due to cost of disease (40). Therefore, 
finding the greatest consumable cost in PID cas-
es and supporting such health cares with sort of 
health coverage and insurance may increase the 
therapeutic compliance of the patients with these 
chronic diseases and subsequently improve the 
number of routine follow-up visits and the quali-
ty of life.  
The cost of anti-infective for systemic use was 
much higher than immune sera and immunoglo-
bulin drugs in our series, which reflect the neg-
lecting about the proportion of these agents in 
total drug costs of PID patients. However, 
pattern of this cost may differ between hospita-
lized patients and out-patients that received im-
munoglobulin products monthly (27).  
Evaluated PID patients had annual mean cost of 
admission 7090.4$ and annual mean cost of phar-
macotherapy of 1579.8$ per admission. The study 
by the Jeffrey Modell Foundation in the US esti-
mated hospitalization cost of each PID patient 
about 16328$ annually. Moreover, hospitalization 
cost annually is about 22223$ in undiagnosed pa-
tient, which differs near to 7000$ with each other. 
Therefore, 40 billion $ saving in the US health care 
system per year by diagnosing people earlier and if 
that is cost of screening is about 5$ per each new-
born baby (41). This could show the importance 
of early diagnosis in preventing complications and 
hospitalization in PID patients. Beside this estima-
tion, the cost in our country seems to be much 
lower than the US, but it may be underestimated 
because of the economic conversion of cost units 
and may be due to environment of this study, 
which held only in a children’s hospital with lower 
needs to drugs dosage. 
It appears pharmacotherapy in these patients is a 
major contribution to the direct costs of PID; 
this does not diminish the other expenses like 
hospital facility costs, and patient evaluating lab 
and diagnostic test. Although as of high risk of 
infection, antibiotics have the most significant 
contribution in drug costs of PID patients; this 
study does not show any significant variability 
between antibiotics and other drug groups. Ac-
cording to the Jeffrey Modell Foundation reports, 
antibiotic therapy for each patient in each episode 
per day is about 4.25$ with 309$ annual cost per 
patient (41).  
Despite these findings, previous studies only fo-
cused on treatment by immunoglobulin agents’ 
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costs, especially in PID patients that need this 
drug as permanent members of the treatment. An 
annual cost of 15.470$ were estimated for intra-
venous immunoglobulin (IVIG) replacement 
therapy in PID patients, which includes both 
costs of admission and outpatient administration. 
Moreover, regular treatment with IVIG can re-
duce cost of nursing and hospitalization and may 
save 2000-5000$ per patient per year (42). 
More than half of PID patients faced some prob-
lems such as avoiding hospitalization, receiving 
insufficient dose of IVIG, or not being visited by 
specialist, because of the medical care costs. In 
addition, at least one fourth of PID individuals 
have complaints about insurance problems (43). 
Although this study focus on the measurement of 
baseline costs of PID, however, this preliminary 
data is required for further health policymaking 
studies inducing measurement of efficiency, ef-
fectiveness, productivity or performance on new 
diagnostic or therapeutic methods. 
 
Conclusion 
 
This study highlights the need for more well-
designed prospective and retrospective studies on 
disease-specific economic burden and costs anal-
ysis. It could provide a good chance for health 
policy makers to plan for PID patients and allo-
cate some fixed budget for early diagnosis of pa-
tients and prevention of further complications 
that exceed the medical care costs. Making some 
structure and strategy, in the end, could be trans-
lated into critical cost saving to an organization.  
 
Ethical considerations 
 
Ethical issues (Including plagiarism, informed 
consent, misconduct, data fabrication and/or fal-
sification, double publication and/or submission, 
redundancy, etc.) have been completely observed 
by the authors.  
 
Acknowledgements 
 
This research was supported by a grant from Te-
hran University of Medical Sciences and Health 
Services (91-02-15-18055). The authors would 
like to thank Mr. Ali Sayyadi, Mrs. Vahideh Pir-
moazzen and Ms. Mina Noei who helped in data 
extraction. The authors declare that there is no 
conflict of interest. 
 
References 
 
1. Picard C, Al-Herz W, Bousfiha A et al (2015). 
Primary Immunodeficiency Diseases: 
an Update on the Classification from the 
International Union of Immunological Societies 
Expert 
Committee for Primary Immunodeficiency 201
5. J Clin Immunol, 53: 696-726. 
2. Papadopoulou-Alataki E, Hassan A, Davies EG 
(2012). Prevention of infection in children and 
adolescents with primary immunodeficiency 
disorders. Asian Pac J Allergy Immunol, 30: 249-58. 
3. Rezaei N, Aghamohammadi A, Moin M et al 
(2006). Frequency and clinical manifestations of 
patients with primary immunodeficiency 
disorders in Iran: update from the Iranian 
Primary Immunodeficiency Registry. J Clin 
Immunol, 26: 519-32. 
4. Aghamohammadi A, Moein M, Farhoudi A et al 
(2002). Primary immunodeficiency in Iran: first 
report of the National Registry of PID in 
Children and Adults. J Clin Immunol, 22: 375-80. 
5. McCusker C, Warrington R (2011). Primary 
immunodeficiency. Allergy Asthma Clin Immunol, 
7 Suppl 1:S11. 
6. Abolhassani H, Sagvand BT, Shokuhfar T, 
Mirminachi B, Rezaei N, Aghamohammadi A 
(2013). A review on guidelines for management 
and treatment of common variable 
immunodeficiency. Expert Rev Clin Immunol, 9: 
561-75. 
7. Aghamohammadi A, Montazeri A, Abolhassani H 
et al (2011). Health-related quality of life in 
primary antibody deficiency. Iran J Allergy 
Asthma Immunol, 10: 47-51. 
8. Errante PR, Franco JL, Espinosa-Rosales FJ, 
Sorensen R, Condino-Neto A (2012). Advances 
in primary immunodeficiency diseases in Latin 
America: epidemiology, research, and 
perspectives. Ann N Y Acad Sci, 1250: 62-72. 
9. Boyle JM, Buckley RH (2007). Population 
prevalence of diagnosed primary 
immunodeficiency diseases in the United States. 
J Clin Immunol, 27: 497-502. 
Gholami et al.: Costs of Hospital Admission on Primary Immunodeficiency … 
 
Available at:    http://ijph.tums.ac.ir                                                                                                        349 
10. Geha RS, Notarangelo LD, Casanova JL et al 
(2007). Primary immunodeficiency diseases: an 
update from the International Union of 
Immunological Societies Primary 
Immunodeficiency Diseases Classification 
Committee. J Allergy Clin Immunol, 120:776-94. 
11. Notarangelo L, Casanova JL, Conley ME et al. 
International Union of Immunological Societies 
Primary Immunodeficiency Diseases 
Classification C (2006). Primary 
immunodeficiency diseases: an update from the 
International Union of Immunological Societies 
Primary Immunodeficiency Diseases 
Classification Committee Meeting in Budapest, 
2005. J Allergy Clin Immunol, 117: 883-96. 
12. Rezaei N, Pourpak Z, Aghamohammadi A et al 
(2006). Consanguinity in primary 
immunodeficiency disorders; the report from 
Iranian Primary Immunodeficiency Registry. 
Am J Reprod Immunol, 56: 145-51. 
13. Farhoudi A, Aghamohammadi A, Moin M et al 
(2005). Distribution of primary 
immunodeficiency disorders diagnosed in the 
Children's Medical Center in Iran. J Investig 
Allergol Clin Immunol, 15: 177-82. 
14. Resnick ES, Bhatt P, Sidi P, Cunningham-Rundles 
C (2013). Examining the use of ICD-9 diagnosis 
codes for primary immune deficiency diseases in 
New York State. J Clin Immunol, 33: 40-8. 
15. Aghamohammadi A, Allahverdi A, Abolhassani H 
et al (2010). Comparison of pulmonary diseases 
in common variable immunodeficiency and X-
linked agammaglobulinaemia. Respirology, 15: 
289-95. 
16. Dedes KJ, Szucs TD, Bodis S et al (2004). 
Management and costs of treating lung cancer 
patients in a university hospital. 
Pharmacoeconomics, 22: 435-44. 
17. Polsky D, Glick H (2009). Costing and cost analysis 
in randomized controlled trials: caveat emptor. 
Pharmacoeconomics, 27: 179-88. 
18. Adam T, Evans DB, Murray CJ (2003). 
Econometric estimation of country-specific 
hospital costs. Cost Eff Resour Alloc, 1: 3. 
19. Abolhassani H, Aghamohammadi A, Abolhassani 
F, Eftekhar H, Heidarnia M, Rezaei N (2011). 
Health policy for common variable 
immunodeficiency: burden of the disease. J 
Investig Allergol Clin Immunol, 21: 454-8. 
20. Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, 
Apkon M (2011). A Markov model to analyze 
cost-effectiveness of screening for severe 
combined immunodeficiency (SCID). Mol Genet 
Metab, 104: 383-9. 
21. McGhee SA, Stiehm ER, McCabe ER (2005). 
Potential costs and benefits of newborn 
screening for severe combined 
immunodeficiency. J Pediatr, 147: 603-8. 
22. Aghamohammadi A, Mohammadinejad P, 
Abolhassani H et al (2014). Primary 
immunodeficiency disorders in Iran: update and 
new insights from the third report of the 
national registry. J Clin Immunol, 34: 478-90. 
23. WHO (2011). International Statistical Classification of 
Diseases and Related Health Problems. ed. World 
Health Organization. 
24. Husty TM, Newell LM (2013). ICD-10: cracking 
the code. Healthc Financ Manage, 67: 32-5. 
25. Hughes C (2012). The anatomy of an ICD-10 
code. Fam Pract Manag, 19: 27-9. 
26. Natsch S, Hekster YA, de Jong R, Heerdink ER, 
Herings RM, van der Meer JW (1998). 
Application of the ATC/DDD methodology to 
monitor antibiotic drug use. Eur J Clin Microbiol 
Infect Dis, 17: 20-4. 
27. Sadeghi B, Abolhassani H, Naseri A, Rezaei N, 
Aghamohammadi A (2015). Economic burden 
of common variable immunodeficiency: annual 
cost of disease. Expert Rev Clin Immunol, 11: 681-
8. 
28. Giuiraud-Chaumeil B (2012). [Intravenous 
immunoglobulins]. Bull Acad Natl Med, 196: 71-
3. 
29. Martin A, Lavoie L, Goetghebeur M, Schellenberg 
R (2013). Economic benefits of subcutaneous 
rapid push versus intravenous immunoglobulin 
infusion therapy in adult patients with primary 
immune deficiency. Transfus Med, 23: 55-60. 
30. Abolhassani H, Sadaghiani MS, Aghamohammadi 
A, Ochs HD, Rezaei N (2012). Home-based 
subcutaneous immunoglobulin versus hospital-
based intravenous immunoglobulin in treatment 
of primary antibody deficiencies: systematic 
review and meta analysis. J Clin Immunol, 32: 
1180-92. 
31. Shapiro RS, Boyle M (2012). Payor issues: barriers 
to optimal management of patients with 
primary immunodeficiency. J Clin Immunol, 32: 
S410-4. 
32. Ballow M (2012). The patient, the physician, and 
the payor: a multiperspective look at the 
Iran J Public Health, Vol. 46, No.3, Mar 2017, pp.342-350  
 
350                                                                                                        Available at:    http://ijph.tums.ac.ir  
challenges of treating primary 
immunodeficiency. J Clin Immunol, 32: S421-2. 
33. Darba J, Restovic G, Kaskens L, de Agustin T 
(2012). Direct medical costs of liquid 
intravenous immunoglobulins in children, 
adolescents, and adults in Spain. J Clin Pharmacol, 
52: 566-75. 
34. Connolly M, Simoens S (2011). Kiovig for primary 
immunodeficiency: reduced infusion and 
decreased costs per infusion. Int 
Immunopharmacol, 11: 1358-61. 
35. Beaute J, Levy P, Millet V et al (2010). Economic 
evaluation of immunoglobulin replacement in 
patients with primary antibody deficiencies. Clin 
Exp Immunol, 160: 240-5. 
36. Simoens S (2009). Pharmacoeconomics of 
immunoglobulins in primary immunodeficie-
ncy. Expert Rev Pharmacoecon Outcomes Res, 9: 375-
86. 
37. van der Spek J, Groenwold RH, van der Burg M, 
van Montfrans JM (2015). TREC Based 
Newborn Screening for Severe Combined 
Immunodeficiency Disease: A Systematic 
Review. J Clin Immunol, 35: 416-30. 
38. Harper JC, Wilton L, Traeger-Synodinos J et al 
(2012). The ESHRE PGD Consortium: 10 
years of data collection. Hum Reprod Update, 
18:234-47. 
39. Latif AH, Tabassomi F, Abolhassani H, 
Hammarstrom L (2014). Molecular diagnosis of 
primary immunodeficiency diseases in a 
developing country: Iran as an example. Expert 
Rev Clin Immunol, 10: 385-96. 
40. Dinakar C (2006). Alleviating disease burden in 
primary immunodeficiency diseases. Ann Allergy 
Asthma Immunol, 96: 260-2. 
41. Anonymus. http://www.info4pi.org/. Access 
2015. 
42. Haddad E, Barnes D, Kafal A (2012). Home 
therapy with subcutaneous immunoglobulins 
for patients with primary immunodeficiency 
diseases. Transfus Apher Sci, 46: 315-21. 
43. Authors (2011). Abstracts of the 2011 CIS (Clinical 
Immunology Society) Annual Meeting. Chicago, 
Illinois, USA. May 19-22, 2011. J Clin Immunol, 
31: S1-71. 
 
 
  
 
 
 
 
 
 
 
 
 
